Literature DB >> 10200261

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists.

Y N Chen1, S K Sharma, T M Ramsey, L Jiang, M S Martin, K Baker, P D Adams, K W Bair, W G Kaelin.   

Abstract

Recent studies identified a short peptide motif that serves as a docking site for cyclin/cyclin-dependent kinase (cdk) 2 complexes. Peptides containing this motif block the phosphorylation of substrates by cyclin A/cdk2 or cyclin E/cdk2. Here we report that cell membrane-permeable forms of such peptides preferentially induced transformed cells to undergo apoptosis relative to nontransformed cells. Deregulation of E2F family transcription factors is a common event during transformation and was sufficient to sensitize cells to the cyclin/cdk2 inhibitory peptides. These results suggest that deregulation of E2F and inhibition of cdk2 are synthetically lethal and provide a rationale for the development of cdk2 antagonists as antineoplastic agents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10200261      PMCID: PMC16331          DOI: 10.1073/pnas.96.8.4325

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals.

Authors:  R Sears; K Ohtani; J R Nevins
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration.

Authors:  H Nagahara; A M Vocero-Akbani; E L Snyder; A Ho; D G Latham; N A Lissy; M Becker-Hapak; S A Ezhevsky; S F Dowdy
Journal:  Nat Med       Date:  1998-12       Impact factor: 53.440

3.  The retinoblastoma protein binds to a family of E2F transcription factors.

Authors:  J A Lees; M Saito; M Vidal; M Valentine; T Look; E Harlow; N Dyson; K Helin
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

4.  Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A.

Authors:  B A Schulman; D L Lindstrom; E Harlow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

5.  Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo.

Authors:  J Fueyo; C Gomez-Manzano; W K Yung; T J Liu; R Alemany; T J McDonnell; X Shi; J S Rao; V A Levin; A P Kyritsis
Journal:  Nat Med       Date:  1998-06       Impact factor: 53.440

Review 6.  Role of the retinoblastoma protein in the pathogenesis of human cancer.

Authors:  W R Sellers; W G Kaelin
Journal:  J Clin Oncol       Date:  1997-11       Impact factor: 44.544

7.  Expression of transcription factor E2F1 induces quiescent cells to enter S phase.

Authors:  D G Johnson; J K Schwarz; W D Cress; J R Nevins
Journal:  Nature       Date:  1993-09-23       Impact factor: 49.962

8.  The cdk2 kinase is required for the G1-to-S transition in mammalian cells.

Authors:  L H Tsai; E Lees; B Faha; E Harlow; K Riabowol
Journal:  Oncogene       Date:  1993-06       Impact factor: 9.867

9.  Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts.

Authors:  M Pagano; R Pepperkok; J Lukas; V Baldin; W Ansorge; J Bartek; G Draetta
Journal:  J Cell Biol       Date:  1993-04       Impact factor: 10.539

10.  Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line.

Authors:  P Boukamp; R T Petrussevska; D Breitkreutz; J Hornung; A Markham; N E Fusenig
Journal:  J Cell Biol       Date:  1988-03       Impact factor: 10.539

View more
  58 in total

1.  Choosing anticancer drug targets in the postgenomic era.

Authors:  W G Kaelin
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  Anticancer drug targets: cell cycle and checkpoint control.

Authors:  G I Shapiro; J W Harper
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 3.  Tossing monkey wrenches into the clock: new ways of treating cancer.

Authors:  J A Lees; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

4.  Polarized distribution of IQGAP proteins in gastric parietal cells and their roles in regulated epithelial cell secretion.

Authors:  Rihong Zhou; Zhen Guo; Charles Watson; Emily Chen; Rong Kong; Wenxian Wang; Xuebiao Yao
Journal:  Mol Biol Cell       Date:  2003-03       Impact factor: 4.138

5.  Bcl-2 activates a programme of premature senescence in human carcinoma cells.

Authors:  Elvira Crescenzi; Giuseppe Palumbo; Hugh J M Brady
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

6.  Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules.

Authors:  Michael H A Roehrl; Sunghyun Kang; José Aramburu; Gerhard Wagner; Anjana Rao; Patrick G Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-06       Impact factor: 11.205

Review 7.  Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality.

Authors:  Frederick Bauzon; Liang Zhu
Journal:  Cell Cycle       Date:  2010-06-01       Impact factor: 4.534

8.  Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors.

Authors:  Padmavathy Nandha Premnath; Shu Liu; Tracy Perkins; Jennifer Abbott; Erin Anderson; Campbell McInnes
Journal:  Bioorg Med Chem       Date:  2013-11-07       Impact factor: 3.641

9.  Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly.

Authors:  Shu Liu; Padmavathy Nandha Premnath; Joshua K Bolger; Tracy L Perkins; Lindsay O Kirkland; George Kontopidis; Campbell McInnes
Journal:  J Med Chem       Date:  2013-02-12       Impact factor: 7.446

10.  Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.

Authors:  Elizabeth Tarasewicz; Lisbi Rivas; Randala Hamdan; Danijela Dokic; Vamsi Parimi; Beatriz Penalver Bernabe; Alexandra Thomas; Lonnie D Shea; Jacqueline S Jeruss
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.